Buy, Sell or Hold: Abbott Labs (ABT-N) — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Abbott Labs (ABT-N)

NYSE:ABT

98.05

1.01 (1.04%) 1d

PAST TOP PICK

(A Top Pick Mar 15/22, Down 15%)

They made the Covid testing kits which generated $20 billion in revenues, so shares got ahead of itself. The market has ignored any such companies since then, but these earnings will eventually work their way up again. ABT has given guidance ex-Covid tests, meaning double-digit organic growth. This is a long-time core holding. They're in medtech and medical procedures are ramping up (a tailwind). Pays a constant and long-growing dividend now around 2.5%. She likes healthcare as a play on the aging population.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Dec 09/22, Down 8%)

Still owns shares in the company.
Believes healthcare a good defensive name.
Target price of $110 per share.
Good performance in the past for the portfolio.
Averaged 16% growth the past 5 years.
Good company for the long term investor.

biotechnology / pharmaceutical

BUY

An emerging market healthcare play.

biotechnology / pharmaceutical

TOP PICK

Believes healthcare will hold up well in recessionary periods Has averaged 16% returns the last 5 years. Consistent earnings growth and profit margins. Large business with diverse revenue model. Has increased dividend the past 50 years.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Oct 13/21, Down 7%) They made Covid test kits and generated $15 billion. They also have medical devices, a division that is improving, and pharmaceuticals that sell generic drugs to emerging markets, and infant formulas, but that ran into troubles. She likes their diversity and has many drugs in the pipeline. It has raised its dividend in the past 50 years. Happy to hold it.

biotechnology / pharmaceutical

BUY

Allan Tong’s Discover Picks Abbott stocks trade at a 25.18x PE at a low 0.74 beta, and pays a 1.73% dividend. Its valuation is significantly lower than peers Stryker (36.4x) and Becton Dickinson (37.3x) while its profit margin scores much higher at 17.35% vs. 11.56% and 9.59% respectively. ROI is also comparably higher while Abbott stock’s 1.73% divvy is in-line with this sector (and safe at a 42.17% payout ratio). Back to earnings: Abbott stocks have beaten their last four quarters handily. Read Our 3 defensive healthcare stocks picks for our full analysis.

biotechnology / pharmaceutical

DON'T BUY

It reports Wednesday. An erratic company, because the Covid-testing business is unpredictable and it will end some day. Until then, this business is terrific. Wall Street doesn't like a business that won't be around in 12 months.

biotechnology / pharmaceutical

BUY

Their last quarter was very good, beating the street, but shares have been down. Part of their growth came from Covid testing, which grew well. Their medical devices business was up 8%, though the last two years halted elective surgeries. This hurt ABT but will improve (like JNJ did) because there's a huge backlog of surgeries. Earnings will grow for several years. He owns Stryker, but likes Abbott a lot.

biotechnology / pharmaceutical

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick May 31/22, Down 10.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $105. To remain disciplined we recommend covering the position at this time. This will result in a net investment loss of 12%, when combined with previous buy recommendations.

biotechnology / pharmaceutical

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly ABT was embroiled in a whistleblower complaint that led to shutdown of a key baby formula plant. Now that the company has effectively been cleared of wrongdoing, the plant will be reopening and we again reiterate ABT as a TOP PICK. Recently reported earnings beat expectations and support at ROE of 28%. The have aggressively bought back shares and are retiring debt early. They are a Dividend Aristocrat, raising dividends for 50 consecutive years. We continue to recommend a stop loss at $105, looking to achieve $143 -- upside potential over 20%. Yield 1.6% (Analysts’ price target is $140.17)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick May 18/21, Down 2%) A diversified healthcare company including diagnostics, nutrtiion, and generic drugs. They made many Covid testing kits, so they benefitted from the pandemic. Shares got hit as the pandemic waned. Still, they've made a lot of money, so they can use that cash flow to buy other companies. The medical devices business will ramp up as surgeries do. Last quarter, their infant formula controversy led them closing their plants; later, ABT was cleared of wrongdoing, so this business will ramp back up. They increase their dividend each year. Pays 2% yield now.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jun 08/21, Up 11%) Still likes. Now above his buy price of $110. Watch and wait for a pullback, as there will be volatility with diagnostics testing winding off.

biotechnology / pharmaceutical

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly ABT has benefited from COVID-19 testing worldwide, is the second largest cardiologic technology company in the world, and is a large player in the continuous glucose monitoring market for diabetes. It trades at 30x earnings, compared to peers at 23x; however, forward earnings support a 23x valuation. It is a little expensive at over 5x book value. It pays a small dividend (that has been growing for 50 years consecutively), backed by a payout ratio under 50% of cash flow. Its most recent earnings beat expectations by 11% and support a strong 27% ROE. It has been building cash reserves while paying down debt. We would recommend setting a stop loss at $105, looking to achieve $143 -- 18% upside potential. Yield 1.59% (Analysts’ price target is $142.88)

biotechnology / pharmaceutical

TOP PICK

Has owned this for years, but is buying at current prices. They make the Covid-testing kits, totalling $10 billion revenues. Demand here will likely soften. The stock price is flat over the year, despite those revenues, but at least the cash flow from the testing can lead to more products and acquisition. They forecast they can grow revenues around 9%. Attractive stock price now. Diagnostic and medical devices are good business. Pharmas are selling to emerging markets. Their glucose monitoring system is doing well. Their heart products are a new source of growth. Attractive PE. (Analysts’ price target is $139.72)

biotechnology / pharmaceutical

TRADE

An excellent company, a leader in medical diagnostics but he is not sure about current positioning. He doesn't want exposure to infectious diseases diagnostics. Wait for the area to act better and interest rates to stabilize.

biotechnology / pharmaceutical

Showing 1 to 15 of 170 entries

«
‹
1
2
3
4
5
›
»

Next Page

Abbott Labs(ABT-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 10

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 10 stock analysts published opinions about ABT-N. 9 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

10 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2023-03-24, Abbott Labs (ABT-N) stock closed at a price of $98.05.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.